Adimmune Corporation Announces Submission of 115 Q2 Consolidated Financial Report to Board of Directors

Release Date: August 6, 115 (2026) Statement Date: August 5, 115 (2026) Statement Time: 15:49:18 Company Code: 4142 Company Name: Adimmune Corporation Subject: Announcement of the submission of the Company's 115 Q2 consolidated financial report to the Board of Directors Applicable Clause: Clause 31 Factual Date: August 5, 115 (2026) Details: 1. Date of submission to or resolution by the Board of Directors: 08/05/115 2. Audit Committee approval date: Not applicable 3. Reporting period for financial report or annual self-prepared financial information (YYY/MM/DD ~ YYY/MM/DD): 115/01/01 ~ 115/06/30 4. Cumulative operating revenue from January 1 to current period end (in NT$ thousands): 149,074 5. Cumulative operating gross profit (loss) from January 1 to current period end (in NT$ thousands): -137,388 6. Cumulative operating income (loss) from January 1 to current period end (in NT$ thousands): -371,933 7. Cumulative pre-tax net profit (loss) from January 1 to current period end (in NT$ thousands): -373,416 8. Cumulative net profit (loss) for the period from January 1 to current period end (in NT$ thousands): -373,416 9. Cumulative net profit (loss) attributable to owners of parent from January 1 to current period end (in NT$ thousands): -345,777 10. Cumulative basic earnings (loss) per share from January 1 to current period end (in NT$): -0.82 11. Total assets at end of period (in NT$ thousands): 8,112,825 12. Total liabilities at end of period (in NT$ thousands): 3,407,897 13. Equity attributable to owners of parent at end of period (in NT$ thousands): 4,624,448 14. Other matters to be disclosed: None